Syndax Pharmaceuticals (SNDX) EBIT: 2015-2024
Historic EBIT for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$339.7 million.
- Syndax Pharmaceuticals' EBIT fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$339.7 million for FY2024, which is 47.71% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its EBIT stood at -$339.7 million for FY2024, which was down 47.71% from -$230.0 million recorded in FY2023.
- Syndax Pharmaceuticals' 5-year EBIT high stood at $26.2 million for FY2021, and its period low was -$339.7 million during FY2024.
- Moreover, its 3-year median value for EBIT was -$230.0 million (2023), whereas its average is -$240.5 million.
- Per our database at Business Quant, Syndax Pharmaceuticals' EBIT spiked by 136.71% in 2021 and then crashed by 678.78% in 2022.
- Over the past 5 years, Syndax Pharmaceuticals' EBIT (Yearly) stood at -$71.4 million in 2020, then soared by 136.71% to $26.2 million in 2021, then crashed by 678.78% to -$151.8 million in 2022, then tumbled by 51.53% to -$230.0 million in 2023, then slumped by 47.71% to -$339.7 million in 2024.